Our Clinician Advisory Board unites experienced professionals from diverse medical specialties to provide critical insights into the challenges of medication access and its impact on patient care. With a deep understanding of the obstacles patients face in accessing essential treatments, these experts play a vital role in championing the preservation of the Six Protected Classes policy. Their practical expertise and strategic guidance strengthen our coalition’s legislative priorities and advocacy efforts, helping to safeguard the policy that helps patients maintain access to the vital medications they need to live.

---

Edward P. Balaban, DO, FACP, FASCO 
Oncologist/Chairperson 
Investigational Review Board, Penn State University 
​Specialty: Oncology 

Rimal B. Bera, MD 
Clinical Professor of Psychiatry 
University of California, Irvine 
​Specialty: Psychiatry 

Rafael Fonseca, MD 
Distinguished Mayo Investigator 
Mayo Clinic of Arizona 
Specialty: Oncology 

Gregory W. Mattingly, MD 
Associate Clinical Professor 
Washington University School of Medicine 
Specialty: Psychiatry 

Michael Measom, MD 
Medical Director/Psychiatrist 
Private Practice 
​Specialty: Psychiatry  

Kathy W. Oubre, MS 
Chief Executive Officer 
Pontchartrain Cancer Center 
Specialty: Oncology 

Hara E. Oyedeji, APRN, PMHNP-BC, MSN, MSEd 
Owner/Clinical Preceptor 
Fortitude Behavioral Health 
Specialty: Psychiatry 

Ruchika Talwar, MD 
Clinical Instructor 
Department of Urology, Vanderbilt University Medical Center 
Specialty: Oncology 

Roaya Tyson, LMHC, LHRM, CAP 
Chief Executive Officer/Mental Health Clinician 
Gracepoint Behavioral Health 
Specialty: Psychiatry 

Mona McCalley-Whitters, PH.D 
Executive Director/Psychologist 
Cedar Rapids Psychiatry PLC 
Specialty: Psychiatry  

Chad Worz, PharmD, BCGP 
CEO/Board Certified Geriatric Pharmacist 
American Society of Consultant Pharmacists (ASCP)  
Specialty: Pharmacy/Geriatrics

For more information on how to get involved, contact [email protected].